CombiGene AB (publ) (COMBI.ST)
SEK 2.34
(1.3%)
SEK 2.34
(1.3%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -35.33 Million SEK | -915.58% |
| 2022 | -5.85 Million SEK | -115.11% |
| 2021 | 23.55 Million SEK | 191.8% |
| 2020 | -25.66 Million SEK | -55.3% |
| 2019 | -16.52 Million SEK | -29.46% |
| 2018 | 83.69 Thousand SEK | -42.5% |
| 2017 | -111.00 SEK | -3.37% |
| 2016 | 30.00 SEK | -358507.15% |
| 2015 | 2418.00 SEK | 180.84% |
| 2014 | 861.00 SEK | 8710.0% |
| 2013 | -10.00 SEK | 99.51% |
| 2012 | -2049.00 SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -7.29 Million SEK | 49.08% |
| 2024 Q1 | -14.54 Million SEK | -137.61% |
| 2023 Q1 | -13.96 Million SEK | -23.68% |
| 2023 Q4 | -8.21 Million SEK | -5.99% |
| 2023 Q3 | -7.75 Million SEK | -37.5% |
| 2023 FY | - SEK | -915.58% |
| 2023 Q2 | -5.63 Million SEK | 59.64% |
| 2022 Q3 | 4.6 Million SEK | -10.92% |
| 2022 FY | - SEK | -115.11% |
| 2022 Q1 | -2.03 Million SEK | -103.5% |
| 2022 Q2 | 5.16 Million SEK | 353.81% |
| 2022 Q4 | -11.29 Million SEK | -345.46% |
| 2021 Q2 | -14.75 Million SEK | -44.55% |
| 2021 Q1 | -10.2 Million SEK | 1.04% |
| 2021 Q3 | -9.57 Million SEK | 35.1% |
| 2021 Q4 | 58.09 Million SEK | 706.69% |
| 2021 FY | - SEK | 191.8% |
| 2020 Q3 | -5.79 Million SEK | -94.4% |
| 2020 Q2 | -2.98 Million SEK | 54.69% |
| 2020 Q1 | -6.57 Million SEK | 20.14% |
| 2020 FY | - SEK | -55.3% |
| 2020 Q4 | -10.31 Million SEK | -78.05% |
| 2019 Q3 | -3 Million SEK | -6.79% |
| 2019 Q4 | -8.23 Million SEK | -174.06% |
| 2019 FY | - SEK | -29.46% |
| 2019 Q1 | -2.47 Million SEK | 7.52% |
| 2019 Q2 | -2.81 Million SEK | -13.83% |
| 2018 Q1 | -1.99 Million SEK | 39.3% |
| 2018 FY | - SEK | -42.5% |
| 2018 Q4 | -2.67 Million SEK | 54.95% |
| 2018 Q3 | -5.93 Million SEK | -174.8% |
| 2018 Q2 | -2.15 Million SEK | -8.0% |
| 2017 Q1 | 249 Thousand SEK | 275.39% |
| 2017 FY | - SEK | -3.37% |
| 2017 Q4 | -3.29 Million SEK | -16.98% |
| 2017 Q3 | -2.81 Million SEK | 9.22% |
| 2017 Q2 | -3.1 Million SEK | -1345.38% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 FY | - SEK | -358507.15% |
| 2016 Q4 | -141.97 Thousand SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q3 | -216 Thousand SEK | 0.0% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 FY | - SEK | 180.84% |
| 2015 Q4 | 218.41 Thousand SEK | 201.12% |
| 2015 Q2 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q4 | 861.00 SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 FY | - SEK | 8710.0% |
| 2013 FY | - SEK | 99.51% |
| 2012 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Active Biotech AB (publ) | -43.88 Million SEK | 19.484% |
| Amniotics AB (publ) | -27.14 Million SEK | -30.185% |
| BioArctic AB (publ) | 275.38 Million SEK | 112.831% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 90.393% |
| Camurus AB (publ) | 562.54 Million SEK | 106.281% |
| Cantargia AB (publ) | -284.31 Million SEK | 87.572% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -80.479% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 74.912% |
| Genovis AB (publ.) | 64.57 Million SEK | 154.723% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 69.248% |
| Mendus AB (publ) | -97.84 Million SEK | 63.886% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 4.559% |
| Intervacc AB (publ) | -68.98 Million SEK | 48.773% |
| Kancera AB (publ) | -61.88 Million SEK | 42.904% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -31.935% |
| LIDDS AB (publ) | -39.67 Million SEK | 10.925% |
| Lipum AB (publ) | -37.11 Million SEK | 4.803% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -191.937% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 212.521% |
| NextCell Pharma AB | -40.98 Million SEK | 13.783% |
| OncoZenge AB (publ) | 7.26 Million SEK | 586.321% |
| Saniona AB (publ) | -69.69 Million SEK | 49.299% |
| Simris Alg AB (publ) | -22.36 Million SEK | -58.011% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 88.869% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 87.471% |
| Xintela AB (publ) | -53.47 Million SEK | 33.915% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 79.191% |
| Ziccum AB (publ) | -20.34 Million SEK | -73.71% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -148.548% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -106.831% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 1766902.9% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 85.129% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -1598.849% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -163.093% |
| Corline Biomedical AB | -1.69 Million SEK | -1989.655% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 79.613% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 35.525% |
| Aptahem AB (publ) | -10 Million SEK | -253.035% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 405.966% |
| Fluicell AB (publ) | -25.91 Million SEK | -36.359% |
| Biovica International AB (publ) | -119.5 Million SEK | 70.432% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 16.313% |
| AcouSort AB (publ) | -16.7 Million SEK | -111.555% |
| Abliva AB (publ) | -93.6 Million SEK | 62.251% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 88.926% |
| 2cureX AB (publ) | -35.13 Million SEK | -0.569% |
| I-Tech AB | 30.34 Million SEK | 216.448% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 95.055% |
| Cyxone AB (publ) | -20.41 Million SEK | -73.097% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 65.51% |
| Biosergen AB | 228 Thousand SEK | 15598.271% |
| Nanologica AB (publ) | -62.11 Million SEK | 43.116% |
| SynAct Pharma AB | -222.7 Million SEK | 84.133% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 19.436% |
| BioInvent International AB (publ) | -312.7 Million SEK | 88.7% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 11520.353% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 84235.475% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 84.744% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -300.978% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 67.45% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -208.101% |